Payment overview · 2025
General Payments
$246.64
12 reported records · 7 companies
Healthcare provider profile · identity verified
Shawn M Peffall, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BALTIMORE, MD · NPI 1457318933
Verified facts
What the public records show
CMS Open Payments records show Shawn M Peffall, M.D. received $246.64 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 34.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $85.41 | 34.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.46 | 19.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.94 | 12.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.14 | 10.6% | 1 | 2025 |
| AERIN MEDICAL INC. | Unresolved — no canonical attribution shown | $25.36 | 10.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.96 | 6.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.37 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $246.64 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.92 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.90 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.94 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.94 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $30.49 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $30.49 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $30.49 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| RHINAER STYLUS Normalized: rhinaer stylus |
Device | AERIN MEDICAL INC. | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| VIVAER STYLUS Normalized: vivaer stylus |
Device | AERIN MEDICAL INC. | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 116 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 452 | 131 |
| Pantoprazole Sodium | Pantoprazole Sodium | 410 | 127 |
| Losartan Potassium | Losartan Potassium | 407 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 115 |
| Metoprolol Succinate | Metoprolol Succinate | 354 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 344 | 92 |
| Lisinopril | Lisinopril | 254 | 73 |
| Zolpidem Tartrate | Zolpidem Tartrate | 236 | 32 |
| Montelukast Sodium | Montelukast Sodium | 214 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 202 | 65 |
| Omeprazole | Omeprazole | 191 | 57 |
| Gabapentin | Gabapentin | 181 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 45 |
| Simvastatin | Simvastatin | 150 | 42 |
| Oxycodone Hcl | Oxycodone Hcl | 145 | 22 |
| Metformin Hcl Er | Metformin Hcl | 142 | 50 |
| Furosemide | Furosemide | 140 | 41 |
| Alprazolam | Alprazolam | 133 | 26 |
| Azelastine Hcl | Azelastine Hcl | 126 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 46 |
| Spironolactone | Spironolactone | 123 | 36 |
| Prednisone | Prednisone | 122 | 90 |
| Metformin Hcl | Metformin Hcl | 120 | 35 |
| Tramadol Hcl | Tramadol Hcl | 120 | 26 |
| Trazodone Hcl | Trazodone Hcl | 119 | 34 |
| Ozempic | Semaglutide | 116 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 37 |
| Celecoxib | Celecoxib | 110 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 30 |
| Bupropion Xl | Bupropion Hcl | 104 | 34 |
| Eliquis | Apixaban | 103 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 31 |
| Jardiance | Empagliflozin | 93 | 22 |
| Finasteride | Finasteride | 92 | 29 |
| Ezetimibe | Ezetimibe | 88 | 27 |
| Carvedilol | Carvedilol | 87 | 25 |
| Allopurinol | Allopurinol | 86 | 24 |
| Pregabalin | Pregabalin | 85 | 21 |
| Valsartan | Valsartan | 84 | 24 |
| Famotidine | Famotidine | 79 | 24 |
| Glipizide Er | Glipizide | 77 | 20 |
| Azithromycin | Azithromycin | 74 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 32 |
| Lorazepam | Lorazepam | 67 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 11 |
| Sertraline Hcl | Sertraline Hcl | 62 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 21 |
| Meloxicam | Meloxicam | 59 | 17 |
| Atenolol | Atenolol | 57 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 40 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 14 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 14 |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Xarelto | Rivaroxaban | 48 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 47 | 42 |
| Synthroid | Levothyroxine Sodium | 47 | 15 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Diazepam | Diazepam | 45 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 35 |
| Ibuprofen | Ibuprofen | 43 | 14 |
| Irbesartan | Irbesartan | 42 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 11 |
| Meclizine Hcl | Meclizine Hcl | 39 | 18 |
| Potassium Chloride | Potassium Chloride | 39 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 15 |
| Levofloxacin | Levofloxacin | 35 | 32 |
| Indapamide | Indapamide | 33 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | 13 |
| Baclofen | Baclofen | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 11 |
| Methylprednisolone | Methylprednisolone | 30 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 19 |
| Colchicine | Colchicine | 26 | 11 |
| Glipizide | Glipizide | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 13 |
| Digoxin | Digoxin | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 17 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $246.64 · 12 records | ABBVIE INC. | CAMZYOS, CREON, LINZESS, OTEZLA, Ozempic, QULIPTA, REPATHA, RHINAER STYLUS, Rybelsus, SHINGRIX, SYNTHROID, The Cologuard Plus Collection Kit, UBRELVY, VIBERZI, VIVAER STYLUS, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error